Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib for Cognitive Decline in Degenerative Dementias
NCT02921477Phase 1Enrolling by invitation
- Sponsor
- Neurological Associates of West Los Angeles
- Start
- Sep 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bosutinib in Mild Cognitive Impairment (MCI) and Dementia, sponsored by Neurological Associates of West Los Angeles. Primary endpoint: Number of patients who are discontinued due to tolerability issues related to treatment at 1 year. Started Sep 2016; status: enrolling by invitation.
02
Drugs
bosutinib
03
Conditions
Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on NCT02921477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921477.